Company Filing History:
3 out of 1,153 
1 out of 10 Years Active: 1998-2000
Title: Harry Kleanthous: Innovator in Peptic Ulcer Research
Introduction
Harry Kleanthous is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of medical research, particularly in understanding peptic ulceration. With a total of 3 patents, Kleanthous has focused on innovative methods for detecting predisposition to gastric conditions.
Latest Patents
Kleanthous's latest patents include groundbreaking work on the TagA gene and methods for detecting predisposition to peptic ulceration. His invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, which is associated with peptic ulceration. The methods he developed involve detecting the presence of a Helicobacter pylori strain that possesses this antigen in a subject. This detection is crucial as it indicates a predisposition to peptic ulceration and gastric carcinoma. Additionally, he has worked on a mutant H. pylori that does not express a functional TagA antigen.
Career Highlights
Throughout his career, Kleanthous has been associated with prestigious institutions such as Vanderbilt University and Oravax, Inc. His work has significantly advanced the understanding of Helicobacter pylori and its implications in gastric health.
Collaborations
Kleanthous has collaborated with esteemed colleagues, including Timothy L. Cover and Martin J. Blaser. These collaborations have further enriched his research and contributions to the field.
Conclusion
Harry Kleanthous is a distinguished inventor whose work on the TagA gene has opened new avenues for understanding and detecting peptic ulceration. His contributions continue to impact medical research and improve patient outcomes.